TECH OUTLOOK 6NOVEMBER 2024EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThe world of anticoagulation therapy is a bit like a chess game: every move--every new study, every regulatory decision--shifts strategies on the board, with the ultimate goal of protecting patients while keeping the deadly risks of clotting and bleeding at bay. And recently, the moves have been fascinating! From the rise of direct oral anticoagulants (DOACs) as the superstar rookies to the development of targeted antidotes that are rewriting the rule book, the game has intensified in the best possible way.Let's start with the DOACs, which include heavy-hitters like apixaban, rivaroxaban, and dabigatran. These agents have firmly nudged the older warfarin into semi-retirement (though not all the way; warfarin just won't quit). With DOACs' simplified dosing and fewer dietary interactions, they're tailor-made for the modern lifestyle where convenience and reliability are paramount. In fact, recent studies have shown these drugs are not just easy to manage but also incredibly effective at reducing stroke risk in atrial fibrillation (AF) patients. They've quickly become the go-to for preventing strokes and treating venous thromboembolism (VTE), given their lower risk of major bleeding compared to traditional therapy. Imagine getting the performance of a warfarin but without the constant monitoring--a win-win that any healthcare provider would cheer on.Yet, no victory comes without some complications. One major issue for DOACs has been the question of reversibility--what happens if a patient on one of these blood thinners starts bleeding uncontrollably? Here's where the real innovation has shone. With the development of reversal agents like idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors, clinicians can now slam the brakes on anticoagulation when things go awry. These antidotes are expensive and not widely available everywhere, so the challenge now is balancing access with cost, especially in emergency settings. But it's a massive leap forward from the days when stopping anticoagulation mid-therapy was a best-guess scenario with limited recourse.In this edition, we have featured Cadrenal Therapeutics, Inc. (Nasdaq: CVKD). The company is a biopharmaceutical company focused on the development of tecarfarin, a late-stage investigational anticoagulant designed to meet the unmet chronic anticoagulation needs of patients with implanted left ventricular devices and rare cardiovascular conditionsThe Impact of DOACs and Reversal Agents on Patient SafetyTECH OUTLOOKCopyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.TECH OUTLOOKNOVEMBER - 11 - 2024, Vol 10 - Issue 16 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: * Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:VisualizerSamael
< Page 5 | Page 7 >